Publications by authors named "James E Foley"

Claim this Profile
I
Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man.
James E Foley

Front Endocrinol (Lausanne)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus.
Marc Evans, Plamen Kozlovski, Päivi M Paldánius, James E Foley, Vaishali Bhosekar

Diabetes Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration.
James E Foley, Bo Ahrén

Eur Endocrinol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance.
Chantal Mathieu, Plamen Kozlovski, Päivi M Paldánius, James E Foley, Vikas Modgill

Eur Endocrinol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DPP-4 inhibitor treatment: β-cell response but not HbA reduction is dependent on the duration of diabetes.
Plamen Kozlovski, Vaishali Bhosekar, James E Foley

Vasc Health Risk Manag· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus.
Marc Evans, Anja Schweizer, James E Foley

Vasc Health Risk Manag· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro lipolysis is associated with whole-body lipid oxidation and weight gain in humans.
Joseph Frankl, Paolo Piaggi, James E Foley, Jonathan Krakoff, Susanne B Votruba

Obesity (Silver Spring)· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
James E Foley, Vaishali Bhosekar, Ryuzo Kawamori

Vasc Health Risk Manag· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes.
Bo Ahrén, James E Foley

Int J Endocrinol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.
Bo Ahrén, James E Foley

Diabetologia· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.
Andrea Tura, Johan Farngren, Anja Schweizer, James E Foley, Giovanni Pacini

Int J Endocrinol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
Wolfgang Kothny, Valentina Lukashevich, James E Foley, Marc S Rendell, Anja Schweizer

Diabetologia· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
Matthias Blüher, Anja Schweizer, Giovanni Bader, James E Foley

Vasc Health Risk Manag· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of vildagliptin on hepatic steatosis.
Mavin Macauley, Kieren G Hollingsworth, Fiona E Smith, Peter E Thelwall, Ahmad Al-Mrabeh, James E Foley

J Clin Endocrinol Metab· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
Marc Evans, Sylvie Dejager, Anja Schweizer, James E Foley

Diabetes Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
Bo Ahrén, James Edward Foley, Sylvie Dejager, Mouna Akacha, Qing Shao

Diabetes Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies.
Bo Ahrén, Chantal Mathieu, Giovanni Bader, Anja Schweizer, James E Foley

Diabetologia· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Anja Schweizer, James E Foley, Wolfgang Kothny, Bo Ahrén

Vasc Health Risk Manag· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Valentina Lukashevich, Anja Schweizer, James E Foley, Sheila Dickinson, Per-Henrik Groop

Vasc Health Risk Manag· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.
Anja Schweizer, Sylvie Dejager, James E Foley

Diabetes Ther· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Johan Farngren, Margaretha Persson, Anja Schweizer, James E Foley, Bo Ahrén

J Clin Endocrinol Metab· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus.
Sylvie Dejager, Anja Schweizer, James E Foley

Vasc Health Risk Manag· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
Mathijs C Bunck, Marieke Poelma, E Marelise Eekhoff, Anja Schweizer, Robert J Heine, James E Foley

J Diabetes· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies.
Anja Schweizer, Sylvie Dejager, James E Foley, Wolfgang Kothny

Vasc Health Risk Manag· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Irfan Vardarli, Michael A Nauck, Lars D Köthe, Carolyn F Deacon, Jens J Holst, James E Foley

J Clin Endocrinol Metab· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis